381.13

1.14% 4.33

United Therapeutics Corp (UTHR)

Overview News Price History Option Chain Financials Why UTHR Down? Discussions Forecast Stock Split

United Therapeutics Corp stock is traded at $381.13, with a volume of 120.60K. It is up +1.14% in the last 24 hours and up +7.07% over the past month. United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Previous Close:

$376.80

Open:

$373.03

24h Volume:

120.60K

Relative Volume:

0.33

Market Cap:

$16.99B

Revenue:

$2.62B

Net Income/Loss:

$1.07B

P/E Ratio:

21.00

EPS:

18.15

Net Cash Flow:

$877.90M

1W Performance:

+8.02%

1M Performance:

+7.07%

6M Performance:

+45.24%

1Y Performance:

+69.81%

1-Day Range:

$373.03

$382.10

1-Week Range:

$343.57

$382.10

52-Week Range:

$208.62

$382.10

United Therapeutics Corp Stock (UTHR) Company Profile

Name

United Therapeutics Corp

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(301) 608-9292

Address

1000 SPRING ST, SILVER SPRING, MD

Employee

1,168

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

UTHR's Discussions on Twitter

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-12-24	Upgrade	Goldman	Sell → Neutral
Feb-05-24	Initiated	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Dec-06-22	Initiated	UBS	Buy
Dec-05-22	Initiated	Goldman	Sell
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jun-25-20	Reiterated	H.C. Wainwright	Neutral
Mar-10-20	Upgrade	Jefferies	Hold → Buy
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Jefferies	Underperform → Hold
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-01-19	Upgrade	Credit Suisse	Neutral → Outperform
May-17-19	Upgrade	UBS	Sell → Neutral
May-09-19	Upgrade	Credit Suisse	Underperform → Neutral
Oct-12-18	Upgrade	Standpoint Research	Hold → Buy
Aug-08-18	Downgrade	Credit Suisse	Neutral → Underperform
Apr-03-18	Upgrade	Credit Suisse	Underperform → Neutral
Feb-22-18	Reiterated	Barclays	Underweight
Jan-18-18	Resumed	Credit Suisse	Underperform
Dec-27-17	Reiterated	Wedbush	Outperform
Apr-27-17	Reiterated	Wedbush	Outperform
Mar-30-17	Initiated	UBS	Sell
Mar-16-17	Initiated	Credit Suisse	Underperform

View All

United Therapeutics Corp Stock (UTHR) Latest News

09:45 AM

United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance

09:45 AM

Nov 04, 2024

Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) - GuruFocus.com

Nov 04, 2024

United Therapeutics Co. (NASDAQ:UTHR) Director Sells $192,081.30 in Stock - MarketBeat

Nov 04, 2024

Sandoz Wins $70M In Antitrust Suit Over Hypertension Drug - Law360

Nov 04, 2024

Sandoz's Award Cut to $71 Million in Generic-Remodulin UTC Case - Bloomberg Law

Nov 04, 2024

Nov 02, 2024

United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 02, 2024

New York State Teachers Retirement System Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Nov 02, 2024

MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN

Nov 02, 2024

Nov 01, 2024

United Therapeutics (NASDAQ:UTHR) Price Target Raised to $302.00 at The Goldman Sachs Group - MarketBeat

Nov 01, 2024

United Therapeutics Q3 Earnings & Sales Beat Estimates - MSN

Nov 01, 2024

United Therapeutics (NASDAQ:UTHR) Hits New 52-Week High on Analyst Upgrade - MarketBeat

Nov 01, 2024

United Therapeutics stock soars to all-time high of $377.93 - Investing.com

Nov 01, 2024

United Therapeutics shares rated Neutral by Ladenburg, target lifted on Tyvaso sales strength - Investing.com Australia

Nov 01, 2024

United Therapeutics shares target raised to $425 by H.C. Wainwright - Investing.com India

Nov 01, 2024

Oct 31, 2024

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by AustralianSuper Pty Ltd - MarketBeat

Oct 31, 2024

United Therapeutics (NASDAQ:UTHR) Announces Quarterly Earnings Results, Beats Expectations By $0.23 EPS - MarketBeat

Oct 31, 2024

Earnings call: United Therapeutics reports robust Q3 growth, eyes future milestones - Investing.com

Oct 31, 2024

United Therapeutics: Q3 Earnings Snapshot - Milford Mirror

Oct 31, 2024

United Therapeutics Corp Q3 2024 Earnings: Revenue Hits $748.9M, EPS at $6.39, Surpassing Estimates - GuruFocus.com

Oct 31, 2024